Medical Crossfire®: Patient and Caregiver Connection™ Getting Beneath the Surface: Addressing Patient Concerns in Moderate to Severe Atopic Dermatitis
Release Date: December 29, 2017 Expiration Date: December 29, 2018 Media: Internet - based
Atopic dermatitis is a chronic, relapsing skin disease which places a significant burden on patients, resulting in a lower quality of life. In moderate-to-severe disease, patients also suffer from high levels of psychological distress, increased prevalence of psychiatric diseases, and increased risk of cardiometabolic comorbidities. During this Medical Crossfire®, dermatology experts will engage in a multidisciplinary roundtable moderated by a family physician with the additional perspective of a patient’s treatment journey as video clips throughout the discussion. Topics covered include disease manifestations, diagnostic criteria, pathophysiology of moderate-to-severe atopic dermatitis and treatment approaches with both current and new and emerging therapies. Faculty will emphasize the importance of individualized treatment plans in a patient-centered approach.
Acknowledgement of Commercial Support
This activity is supported by independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Instructions for This Activity and Receiving Credit
You will need to login to participate in the activity.
Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
At the end of the activity, “educational content/video files” will be available for your reference.
In order to receive a CME/CE certificate, participants must complete the activity.
Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.
This activity is directed to dermatologists, allergists, immunologists, rheumatologists, primary care physicians, researchers; other healthcare professionals interested in the treatment of Atopic Dermatitis are invited to participate.
At the completion of this activity, you should be better prepared to:
Outline the burden of atopic dermatitis (AD) on patients.
Discuss the most recent information on the epidemiology and pathogenesis of AD, and how this is likely to affect the management of patients with AD.
Analyze how older and newer therapies fit into the AD treatment paradigm.
Clarify how a multidisciplinary, patient-centered, approach to care may improve patient outcomes in AD.
Paul P. Doghramji, MD, FAAFP Attending Physician, Collegeville Family Practice Medical Director, Health Services, Ursinus College, Collegeville, PA Cofounder, Brookside Family Practice and Pediatrics Assistant Medical Director, Health Services, Hill School, Pottstown, PA Disclosure: No relevant financial relationships with commercial interests
Peter Lio, MD Assistant Clinical Professor Dermatology and Pediatrics Northwestern University, Feinberg School of Medicine Chicago, Illinois Disclosure: Grant/Research Support: AOBIOME, Pierre-Fabre; Consultant: AOBiome, Anacor, L’Oreal, Pfizer, Regeneron/Sanofi, Theraplex, Valeant; Speakers Bureau: L’Oreal, Pfizer, Regeneron/Sanofi
Christine Go, MMS, PA-C Leone Dermatology Arlington Heights, Illinois Disclosure: No relevant financial relationships with commercial interests Pamela P. Fantus, RN, MSN Patient Disclosure: No relevant financial relationships with commercial interests
The staff of PER® have no relevant financial relationships with commercial interests to disclose.
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI. Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process. The staff of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.
Atopic dermatitis is a chronic skin disease that occurs mostly in children, but also in adults.1 It is a pruritic, inflammatory disease that follows a relapsing course. The hallmark of atopic dermatitis is pruritus, which is responsible for much of the disease burden. Of the patients who develop atopic dermatitis as children, 10% to 30% of patients do not have disease resolution by adulthood. The pathophysiology is not completely understood; however, immunologic, genetic, and environmental factors contribute to skin barrier dysfunction and immunologic dysregulation.2 Clinical findings include erythema, edema, xerosis, erosions/excoriations, oozing, crusting, and lichenification.1
The 2 biggest risk factors for the development of atopic dermatitis are a positive family history and loss of function mutations in the filaggrin (FLG) gene.1 There is a positive family history in approximately 70% of patients with atopic dermatitis, with a maternal history possibly more predictive of disease. Filaggrin degradation proteins play a role in formation of the skin barrier. Byproducts of FLG contribute to epidermal hydration. Not all patients with atopic dermatitis will have loss of function mutations in the FLG gene. Environmental risk factors and microbial exposure may also contribute to the development of atopic dermatitis.3Advances in the identification of risk factors may result in early, aggressive therapy for patients who are diagnosed at the beginning stages of the disease process.
Living with atopic dermatitis can have a significant negative impact on the patient and caregivers.4 Changes in physical appearance can result in social and emotional stress. Sleep disturbance, anxiety, and depression are not uncommon in these patients and their families. In a study comparing quality of life and absenteeism in individuals with and without atopic dermatitis, the incidence of depression, anxiety, sleep disturbance, and absenteeism was significantly higher in individuals with atopic dermatitis.5 Annual costs in the United States associated with atopic dermatitis are approximately $5.297 billion, which is a conservative estimate.6 As we learn more about atopic dermatitis, new and emerging therapies, including targeted therapies, will have a significant impact on disease management.
Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis. Part 1: Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-351. doi: 10.1016/j.jaad.2013.10.010.
Montes-Torres A, Llama-Velasco M, Pérez-Plaza, A, Solano-López G, Sánchez-Pérez J. Biologic treatments in atopic dermatitis. J Clin Med. 2015;4(4):593-613. doi: 10.3390/jcm4040593.
Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(suppl 1):8-16. doi: 10.1159/000370220.
Lifschitz C. The impact of atopic dermatitis on quality of life. Ann Nutr Metab. 2015;66(suppl 1):34-40. doi: 10.1159/000370226.
Eckerd L, Gupta S, Amand C, et al. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey. J Am Acad Dermatol. 2017;77(2):274-279.e3. doi: 10.1016/j.jaad.2017.04.019.
Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30. doi: 10.1016/j.jid.2016.07.012.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.